Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Sci Rep ; 14(1): 6418, 2024 03 17.
Artigo em Inglês | MEDLINE | ID: mdl-38494515

RESUMO

Respiratory viruses can cause life-threatening illnesses. The focus of treatment is on supportive therapies and direct antivirals. However, antivirals may cause resistance by exerting selective pressure. Modulating the host response has emerged as a viable therapeutic approach for treating respiratory infections. Additionally, considering the probable future respiratory virus outbreaks emphasizes the need for broad-spectrum therapies to be prepared for the next pandemics. One of the principal bioactive constituents found in the seed extract of Aesculus hippocastanum L. (AH) is ß-escin. The clinical therapeutic role of ß-escin and AH has been associated with their anti-inflammatory effects. Regarding their mechanism of action, we and others have shown that ß-escin and AH affect NF-κB signaling. Furthermore, we have reported the virucidal and broad-spectrum antiviral properties of ß-escin and AH against enveloped viruses such as RSV, in vitro and in vivo. In this study, we demonstrate that ß-escin and AH have antiviral and virucidal activities against SARS-CoV-2 and CCoV, revealing broad-spectrum antiviral activity against coronaviruses. Likewise, they exhibited NF-κB and cytokine modulating activities in epithelial and macrophage cell lines infected with coronaviruses in vitro. Hence, ß-escin and AH are promising broad-spectrum antiviral, immunomodulatory, and virucidal drugs against coronaviruses and respiratory viruses, including SARS-CoV-2.


Assuntos
Aesculus , COVID-19 , Vírus , Escina/farmacologia , SARS-CoV-2/metabolismo , Aesculus/metabolismo , NF-kappa B/metabolismo , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Vírus/metabolismo , Antivirais/farmacologia , Antivirais/uso terapêutico
2.
Artigo em Inglês | MEDLINE | ID: mdl-37682578

RESUMO

Introduction: Cannabidiol (CBD), the main non-psychoactive cannabinoid of the Cannabis sativa plant, is a powerful antioxidant compound that in recent years has increased interest due to causes effects in a wide range of biological functions. Zika virus (ZIKV) is a virus transmitted mainly by the Aedes aegypti mosquitoes, which causes neurological diseases, such as microcephaly and Guillain-Barre syndrome. Although the frequency of viral outbreaks has increased recently, no vaccinations or particular chemotherapeutic treatments are available for ZIKV infection. Objectives: The major aim of this study was to explore the in vitro antiviral activity of CBD against ZIKV, expanding also to other dissimilar viruses. Materials and Methods: Cell cultures were infected with enveloped and nonenveloped viruses and treated with non-cytotoxic concentrations of CBD and then, viral titers were determined. Additionally, the mechanism of action of the compound during ZIKV in vitro infections was studied. To study the possible immunomodulatory role of CBD, infected and uninfected Huh-7 cells were exposed to 10 µM CBD during 48 h and levels of interleukins 6 and 8 and interferon-beta (IFN-ß) expression levels were measured. On the other hand, the effect of CBD on cellular membranes was studied. For this, an immunofluorescence assay was performed, in which cell membranes were labeled with wheat germ agglutinin. Finally, intracellular cholesterol levels were measured. Results: CBD exhibited a potent antiviral activity against all the tested viruses in different cell lines with half maximal effective concentration values (CE50) ranging from 0.87 to 8.55 µM. Regarding the immunomodulatory effect of CBD during ZIKV in vitro infections, CBD-treated cells exhibited significantly IFN-ß increased levels, meanwhile, interleukins 6 and 8 were not induced. Furthermore, it was determined that CBD affects cellular membranes due to the higher fluorescence intensity that was observed in CBD-treated cells and lowers intracellular cholesterol levels, thus affecting the multiplication of ZIKV and other viruses. Conclusions: It was demonstrated that CBD inhibits structurally dissimilar viruses, suggesting that this phytochemical has broad-spectrum antiviral effect, representing a valuable alternative in emergency situations during viral outbreaks, like the one caused by severe acute respiratory syndrome coronavirus 2 in 2020.

3.
Viruses ; 15(4)2023 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-37112969

RESUMO

New antiviral treatments are needed to deal with the unpredictable emergence of viruses. Furthermore, vaccines and antivirals are only available for just a few viral infections, and antiviral drug resistance is an increasing concern. Cyanidin (a natural product also called A18), a key flavonoid that is present in red berries and other fruits, attenuates the development of several diseases, through its anti-inflammatory effects. Regarding its mechanism of action, A18 was identified as an IL-17A inhibitor, resulting in the attenuation of IL-17A signaling and associated diseases in mice. Importantly, A18 also inhibits the NF-κB signaling pathway in different cell types and conditions in vitro and in vivo. In this study, we report that A18 restricts RSV, HSV-1, canine coronavirus, and SARS-CoV-2 multiplication, indicating a broad-spectrum antiviral activity. We also found that A18 can control cytokine and NF-κB induction in RSV-infected cells independently of its antiviral activity. Furthermore, in mice infected with RSV, A18 not only significantly reduces viral titers in the lungs, but also diminishes lung injury. Thus, these results provide evidence that A18 could be used as a broad-spectrum antiviral and may contribute to the development of novel therapeutic targets to control these viral infections and pathogenesis.


Assuntos
Antivirais , COVID-19 , Camundongos , Animais , Antivirais/farmacologia , Antivirais/uso terapêutico , SARS-CoV-2/metabolismo , NF-kappa B/metabolismo , Interleucina-17 , Flavonoides/farmacologia
5.
J Neurooncol ; 118(2): 205-223, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24771286

RESUMO

Tuberous sclerosis complex (TSC) is a genetic condition with multisystem involvement, characterized by the development of tumors and other abnormalities in organs such as the brain, retina, skin, heart, kidneys, and lungs. Most patients have neuropathological abnormalities such as cortical tubers, white matter radial migration lines, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs). These lesions are associated with different neurological manifestations that are frequently associated with TSC. These manifestations consist of epilepsy, intellectual disability, and neurobehavioral and psychiatric problems, including autism spectrum disorder. Hydrocephalus may also develop in patients with SEGAs due to ventricular obstruction, when this usually slow-growing tumor reaches sufficient size. Surgery has been the classical approach to treat SEGAs, although this treatment is associated with substantial morbidity and does not completely prevent tumor recurrence. Recently, the mammalian target of rapamycin (mTOR) inhibitor, everolimus, has been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of patients with SEGAs associated with TSC. However, the treatment of SEGAs with these agents requires the development of guidelines that establish a differential diagnosis between SENs and SEGAs, in which neuroradiological examinations play an essential role. With the aim of improving the neuroradiological diagnosis and follow-up of the neuropathological abnormalities associated with TSC, a group of experts in this field has reviewed different aspects related to these issues and put together, a series of statements and recommendations intended to provide guidance to specialists involved in the management of TSC.


Assuntos
Encefalopatias/diagnóstico por imagem , Encefalopatias/etiologia , Encéfalo/diagnóstico por imagem , Neuroimagem/métodos , Esclerose Tuberosa/complicações , Esclerose Tuberosa/diagnóstico por imagem , Astrocitoma/diagnóstico , Astrocitoma/diagnóstico por imagem , Astrocitoma/terapia , Encéfalo/patologia , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/terapia , Diagnóstico Diferencial , Humanos , Radiografia , Ultrassonografia Pré-Natal
6.
Radiología (Madr., Ed. impr.) ; 42(4): 266-269, mayo 2000. ilus
Artigo em Es | IBECS | ID: ibc-4596

RESUMO

El linfoma primario tiroideo es una neoplasia infrecuente, sobre todo en los niños. Presentamos un caso de una niña con linfoma Burkitt tiroideo como única manifestación de esta enfermedad, asociado a tiroiditis linfocitaria. Clínicamente debutó como bocio de rápido crecimiento con sintomatología compresiva. Se describen los hallazgos radiológicos: múltiples nódulos que afectan a lóbulo tiroideo derecho e istmo, hipoecogénicos e hipodensos, con extensión extraglandular a espacio vascular y a mediastino. Se plantea el diagnóstico diferencial con otras patologías tiroideas más frecuentes en este grupo de edad (AU)


Assuntos
Feminino , Criança , Humanos , Linfoma de Burkitt/complicações , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt , Tomografia Computadorizada por Raios X/métodos , Tireoidite Autoimune/complicações , Tireoidite Autoimune/diagnóstico , Tireoidite Autoimune , Glândula Tireoide/patologia , Glândula Tireoide , Bócio/complicações , Bócio/diagnóstico , Bócio/etiologia , Bócio , Tireoidite Autoimune/epidemiologia , Tireoidite Autoimune/fisiopatologia , Infecções Oportunistas/complicações , Infecções Oportunistas/diagnóstico , Infecções Oportunistas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...